Top

Published in:

01-04-2012 | Original Article

Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis

Authors: Qian Xing, Bin Wang, Houheng Su, Jiajia Cui, Jinghua Li

Published in: Rheumatology International | Issue 4/2012

Abstract

To investigate the variations of T-helper 17 (Th17) and regulatory T (Treg) cells in patients with lupus nephritis (LN), a total of 60 systemic lupus erythematosus patients and 28 healthy controls (HCs) were enrolled. The frequency of Th17 cells and Treg cells in peripheral blood mononuclear cells (PBMCs) was evaluated by flow cytometric analysis. The serum concentrations of interleukin-17 (IL-17) and transforming growth factor-beta 1 (TGF-β1) were measured by enzyme-linked immunosorbent assay (ELISA). The results demonstrated in LN patients a significant decrease in the frequency of CD4+CD25^high and CD4+CD25+FoxP3+ T cells and a significant increase in the frequency of Th17 cells in peripheral blood, and the ratio of Th17 to Treg cell frequency was significantly increased along with increased SLEDAI scores. LN patients had a lower percentage and expression of FoxP3 in CD4+CD25^high T cells than SLE patients without nephritis. The concentration of TGF-β1 was found decreased in SLE patients compared with that from healthy controls, though no significant difference was found between LN patients and SLE patients without nephritis. The expression of IL-17 levels in LN patients exhibited a significant increase compared with patients without nephritis and healthy controls. Based on our results, the significantly elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in lupus nephritis, suggesting that Th17/Treg functional imbalance may be involved in the pathogenesis of renal damage in SLE patients.

Heinlen LD, McClain MT, Merrill J et al (2007) Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthr Rheum 56:2344–2351CrossRef

Mok CC, Ying KY, Ng WL et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119:355.e25–355.e33CrossRef

Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517PubMedCrossRef

Nalbandian A, Crispin JC, Tsokos GC (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 157:209–215PubMedCrossRef

Crispin JC, Oukka M, Bayliss G et al (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181:8761–8766PubMed

Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef

Brenda A, Berenice HC, Diana P et al (2006) Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 27:110–118CrossRef

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 40:1725CrossRef

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthr Rheum 35:630–640CrossRef

10.

Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336PubMedCrossRef

11.

Ochs HD, Oukka M, Torgerson TR (2009) TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 123:977–983PubMedCrossRef

12.

Pan HF, Ye DQ, Li XP (2008) Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 4:352–353PubMed

13.

Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef

14.

Afzali B, Lombardi G, Lechler RI, Lord GM (2007) The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148:32–46PubMedCrossRef

15.

Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25^high regulatory cells in human peripheral blood. J Immunol 167:1245–1253PubMed

16.

Yagi H, Nomura T, Nakamura K et al (2004) Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 16:1643–1656PubMedCrossRef

17.

Gavin MA, Rasmussen JP, Fontenot JD et al (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445:771–775PubMedCrossRef

18.

Wan YY, Flavell RA (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445:766–770PubMedCrossRef

19.

Mellor-Pita S, Citores MJ, Castejon R et al (2006) Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis 65:553–554PubMedCrossRef

20.

Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E (2007) Measurement of natural (CD4+CD25^high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 16:489–496PubMedCrossRef

21.

Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S (2008) Dysfunctional CD4+CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α-producing antigen-presenting cells. Arthr Rheum 58:801–812CrossRef

22.

Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR, Yoo WH (2008) Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology 47:789–794PubMedCrossRef

23.

Crispin JC, Martinez A, Alcocer-Varela J (2003) Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21:273–276PubMedCrossRef

24.

Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE (2008) Clinical significance of increased CD4+CD25-FoxP3+T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 67:1037–1040PubMedCrossRef

25.

Bonelli M, Savitskaya A, Dalwigk KV et al (2008) Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 20:861–868PubMedCrossRef

26.

Vargas-Rojas MI, Crispín JC, Richaud-Patin Y, Alcocer-Varela J (2008) Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 17:289–294PubMedCrossRef

27.

Zhang B, Zhang X, Tang FL, Zhu L, Liu Y (2008) Reduction of forkhead box P3 levels in CD4+CD25 high T cells in patients with new onset systemic lupus erythematosus. Clin Exp Immunol 153:182–187PubMedCrossRef

28.

Abe J, Ueha S, Suzuki J et al (2008) Increased Foxp3+CD4+ Regulatory T Cells with Intact Suppressive Activity but Altered Cellular Localization in Murine Lupus. Am J Pathol 173:1682–1692PubMedCrossRef

29.

Zhou L, Lopes JE, Chong MM et al (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453:236–240PubMedCrossRef

30.

Langrish CL, Chen Y, Blumenschein WM et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240PubMedCrossRef

31.

Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177PubMed

32.

Dong GF, Ye RG, Shi W et al (2003) IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 116:543–548

33.

Kang HK, Liu M, Datta SK (2007) Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 178:7849–7858PubMed

34.

Hsu HC, Yang P, Wang J et al (2008) Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9:166–175PubMedCrossRef

35.

Chen XQ, Yu YC, Deng HH et al (2010) Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol 30:221–225PubMedCrossRef

Title: Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis
Authors: Qian Xing
Bin Wang
Houheng Su
Jiajia Cui
Jinghua Li
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 4/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1771-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Asymmetrical hemochromatosis arthropathy in a patient with a history of poliomyelitis

The prevalences of some rheumatic diseases in western Turkey: Havsa study

The association between dermatomyositis and papillary thyroid cancer: a case report

Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India

Cross-cultural adaptation and validation of the knee and hip health-related quality of life (OAKHQoL) in a Moroccan Arabic-speaking population

Greek NHS capacity constraints regarding intravenous treatment for rheumatoid arthritis patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials